From: Regional industrial growth and biopharma patent networks: empirical insights from the UK
Average numbers | amigain_1976 | amigain_2010 | Average Growths | amigain_1976 | amigain_2010 |
---|---|---|---|---|---|
avg_Ntotal | 0.1559 | −0.0439 | avg_Gtotal | −0.0857 | −0.2189 |
88 | 54 | 88 | 54 | ||
avg_NBPCore | 0.0579 | −0.2621* | avg_GBPCore | 0.0616 | −0.0951 |
81 | 53 | 81 | 53 | ||
avg_NMTCore | 0.1838* | 0.0807 | avg_GMTCore | −0.0915 | −0.2790* |
88 | 54 | 88 | 54 | ||
avg_NBPSvc | 0.0804 | −0.1039 | avg_GBPSvc | −0.0012 | −0.0753 |
87 | 54 | 87 | 54 | ||
avg_NMTSvc | 0.2453* | 0.0555 | avg_GMTSvc | −0.0588 | −0.1979 |
87 | 54 | 87 | 54 | ||
avg_Nt1 | 0.2002* | −0.0221 | avg_Gt1 | −0.0649 | −0.0716 |
88 | 54 | 88 | 54 | ||
avg_Nt2 | 0.1341 | −0.0580 | avg_Gt2 | −0.0384 | 0.1431 |
86 | 54 | 86 | 54 | ||
avg_Nt3 | 0.1545 | −0.0422 | avg_Gt3 | 0.0757 | 0.0307 |
86 | 54 | 86 | 54 | ||
avg_Nt4 | 0.1590 | −0.0684 | avg_Gt4 | −0.1662 | 0.0399 |
87 | 54 | 87 | 54 | ||
avg_Nt5 | 0.1795* | 0.0713 | avg_Gt5 | −0.1063 | −0.1869 |
87 | 54 | 87 | 54 | ||
avg_Nt6 | 0.1836* | −0.0127 | avg_Gt6 | 0.0193 | 0.0215 |
87 | 54 | 87 | 54 | ||
avg_Nt7 | 0.0611 | −0.1220 | avg_Gt7 | 0.0500 | −0.1919 |
88 | 54 | 88 | 54 | ||
avg_Ne1 | 0.1602 | −0.0690 | avg_Ge1 | −0.0011 | −0.0631 |
88 | 54 | 88 | 54 | ||
avg_Ne2 | 0.2173* | −0.0205 | avg_Ge2 | −0.2739* | −0.3216* |
87 | 54 | 87 | 54 | ||
avg_Ne3 | 0.1723 | 0.0807 | avg_Ge3 | −0.1780* | −0.1761 |
87 | 54 | 87 | 54 | ||
avg_Ne4 | 0.1159 | −0.0614 | avg_Ge4 | −0.1567 | −0.2451* |
86 | 54 | 86 | 54 | ||
avg_Ne5 | 0.1029 | −0.1241 | avg_Ge5 | −0.0489 | −0.2505* |
83 | 52 | 83 | 52 | ||
avg_Ne6 | 0.0764 | −0.0381 | avg_Ge6 | −0.1560 | 0.0059 |
83 | 52 | 83 | 52 | ||
avg_Ne7 | 0.0643 | −0.1740 | avg_Ge7 | 0.1187 | 0.1953 |
78 | 52 | 78 | 52 |